Dr. Levy is an experienced organic/medicinal chemist having contributed to the design of novel therapeutic agents targeting cardiovascular disease, cancer and inflammatory disorders. In his 20 years of contributing to the biopharmaceutical industry, Dr. Levy led interdisciplinary teams focused on kinase inhibitors, GPCR antagonists, matrix metalloproteinase inhibitors and cell adhesion molecules. His work is documented in almost 30 peer reviewed publications and over 11 issued/published United States patents.
Having held positions at Glycomed, COR Therapeutics and Scios, Dr. Levy's most recent role was Director of Synthetic Chemistry at Intradigm Corporation designing novel nanopartical delivery vehicles siRNA-based therapeutics. He has broad experience in the chemistry of amino acids/peptides, sugars/carbohydrates, heterocycles, polyethylene glycols and lipids. As a consultant, Dr. Levy provides strategic guidance and program implementation services to companies interested in small molecule drug discovery/development, diagnostics, drug delivery and microfluidics. Set-up and management of outsourcing activities is a key service supporting these sectors. Additionally, he provides technical due diligence services, facilitates intellectual property development and supports the filing of grant application.
Dr. Levy received his Ph.D. in organic chemistry from the Massachusetts Institute of Technology and his B.S. in chemistry from the University of California - Berkeley. He is the author/editor of three books addressing aspects of carbohydrate chemistry and mechanistic organic chemistry.